WEBINAR SERIES
Microbiome on the Cloud: A Case Study and Demo of the New Sigma-Aldrich® Bioinformatics Database and Software for 16S Analysis
Translating Microbiome research from the lab bench to patients is a current challenge in the field due to the lack of reproducibility, caused by variables that can be introduced from sample collection upstream to statistical software used downstream. There is a growing need for robust tools and protocols that will enable safe adoption of microbiome studies while developing intervention or prevention strategies such as manipulations of diet and microbiome-based therapeutics.
MilliporeSigma offers a variety of Microbiome products for detection and standardization as well as a multi-omic service package, including the new Sigma-Aldrich® cloud-based platform for bioinformatics analysis. In this webinar, we will demo the ease of use and flexibility of the Sigma-Aldrich® 16S software to analyze large sample data sets and generate publication ready figures. We include unlimited data access and storage as well as in depth consultation with the experts in R&D and Bioinformatics at the start and finish of a project.
In this webinar, the presenters will do a deep dive into a case study of DNA extraction and sequencing that we’ve performed for one of our customers. We will demonstrate how we utilized Sigma-Aldrich® products and validated protocols to answer the customer’s key questions. We are offering every registrant a free of charge access to the Sigma-Aldrich® Microbiome platform for 16S analysis in 2020.
Presenters:
Andrew Schriefer
Bioinformatic Data Scientist
MilliporeSigma
Andrew Schriefer is responsible for designing and validating the 16s-seq and WGS metagenomic analysis pipelines used in the Sigma-Aldrich metagenome webapp. Andrew also provides bioinformatic support to help optimize the microbiome Illumina sequencing workflows.
Before he joined MilliporeSigma, Andrew worked for Washington University in St. Louis as a bioinformatician assisting academic researchers with their Next Generation Sequencing projects.
Michal Daniely, Ph.D.
Director of R&D
Merck KGaA
Michal Daniely Ph.D. is the director of research and development for Merck KGaA, Darmstadt, Germany at the Jerusalem & Rehovot locations in Israel. Dr. Daniely is responsible for developing technologies and products for a wide range of research applications -- using core technologies such as: microbial fermentation, recombinant proteins design & expression, Next Generation Sequencing (NGS), Mass Spectrometry (MS), and antibodies development (monoclonal & polyclonal).
Over the past three years, Dr. Daniely has been deeply involved in shaping the company’s strategy within the microbiome research field -- aiming to develop products and technologies to support the growing need in this market.
Dr. Daniely earned her MSc & PhD in Human Genetics from the Sackler Medical School, Tel Aviv University, Israel. Prior to joining Merck KGaA, Darmstadt, Germany, she held various roles with medical device and pharma companies, where she managed the research & development activities.
Date: June 17, 2020
Time: 1:00 pm Central Daylight
Brought to you by Arrowhead Publishers, the organizers of the:
Registrant agrees to receive all e-mails specific to the webinar they are registering for, including a post-webinar sales follow-up from the sponsor of this webinar.
Sponsored by:
